Every Form 4 that U S Physical Therapy (USPH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow USPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full USPH filings page.
U S PHYSICAL THERAPY INC /NV (USPH) reported that President and COO Eric Joseph Williams surrendered 714 shares of Common Stock on August 20, 2026 at $78.00 per share to the company to satisfy applicable tax withholding obligations upon the vesting of equity awards. After this tax-withholding disposition, he directly holds 39,617 shares, including 24,402 shares of restricted stock granted under the Company's Amended and Restated 2003 Stock Incentive Plan.
The filing details a vesting schedule for these restricted shares running through March 6, 2030, with specific tranches vesting on multiple dates each year. Vesting remains subject to his continued employment with the company through each applicable vesting date.
U S PHYSICAL THERAPY INC /NV (USPH) reported that officer CURTIS JASON TRAVIS, Interim CFO, surrendered 40 shares of common stock on August 20, 2026 to the issuer to satisfy tax withholding obligations upon vesting of equity awards, at a reference price of $78.00 per share. After this tax-withholding disposition, he directly holds 3,853 shares of common stock, including 3,425 shares of restricted stock that will vest in scheduled tranches between November 20, 2026 and March 6, 2030, contingent on continued service.
U S PHYSICAL THERAPY INC /NV (USPH) reported that executive vice president, general counsel and secretary Richard Binstein surrendered 450 shares of common stock on August 20, 2026 at $78.00 per share. The shares were delivered to the issuer to satisfy tax withholding obligations upon vesting. After this disposition, he directly holds 24,417 shares, including 17,330 shares of restricted stock scheduled to vest in tranches through March 6, 2030, contingent on continued employment.
U S PHYSICAL THERAPY INC /NV (USPH) reported that its COO, Graham D. Reeve, surrendered 762 shares of common stock on August 20, 2026 to the company to satisfy tax withholding obligations upon vesting of equity awards. After this tax-withholding disposition, he directly holds 28,554 shares, including 17,488 shares of restricted stock scheduled to vest in tranches through March 6, 2030 if he remains employed.
U.S. Physical Therapy interim CFO Jason Travis surrendered 40 shares of common stock at $62.24 per share to satisfy tax withholding obligations when restricted stock vested.
After this tax-withholding disposition, he directly holds 3,893 shares, including 3,596 restricted shares scheduled to vest over multiple dates through 2030, contingent on continued service.
U.S. Physical Therapy COO Graham D. Reeve reported a routine share disposition related to taxes. On May 20, he surrendered 762 shares of Common Stock at $62.24 per share to the company to satisfy tax withholding obligations upon vesting of equity awards. After this transaction, he directly holds 29,316 shares, including 19,436 restricted shares that are scheduled to vest in tranches from August 20, 2026 through March 6, 2030, contingent on continued employment.
U.S. Physical Therapy director Peter Francis Minan reported buying company stock in the open market. He purchased 492 shares of common stock on June 8, 2026 at $63.14 per share and 288 shares on June 9, 2026 at $61.50 per share, totaling 780 shares.
After these trades, he directly holds 3,211 common shares. Footnotes state this includes 2,306 shares granted as restricted stock, with restrictions scheduled to lapse on August 20, 2026, November 20, 2026, and March 6, 2027 if he remains a director on those dates.
Swanson Regg E. reported acquisition or exercise transactions in this Form 4 filing.
U.S. Physical Therapy director Regg E. Swanson reported a stock award and updated holdings. He received a grant of 2,306 shares of common stock at a reported price of $0.00 per share as a compensation-related award.
The filing notes this corrects a prior report that had used $61.61 as the transaction price. Following the award, Swanson holds 15,492 shares directly and 7,596 shares indirectly through the Regg E. Swanson Revocable Trust, where he is beneficiary and trustee.
The 2,306 restricted shares vest in tranches: 1,153 shares on August 20, 2026, 576 shares on November 20, 2026, and 577 shares on March 6, 2027, if he remains a director on those dates.
Motsenbocker Anne reported acquisition or exercise transactions in this Form 4 filing.
U.S. Physical Therapy director Anne Motsenbocker received an equity grant of 2,306 shares of common stock on May 19, 2026. The shares were granted at $0.00 as restricted stock under the company’s Amended and Restated 2003 Stock Incentive Plan, bringing her direct holdings to 9,812 shares.
The restrictions lapse in stages if she continues as a director: 1,153 shares on August 20, 2026, 576 shares on November 20, 2026, and 577 shares on March 6, 2027.
Minan Peter Francis reported acquisition or exercise transactions in this Form 4 filing.
U.S. Physical Therapy director Peter Francis Minan received a grant of 2,306 shares of common stock as a stock award, with a corrected transaction price of $0.00 per share. This award was issued as restricted stock under the company’s Amended and Restated 2003 Stock Incentive Plan.
Following the grant, he holds 2,431 shares directly. The restrictions on these 2,306 shares lapse in stages: 1,153 shares on August 20, 2026, 576 shares on November 20, 2026, and 577 shares on March 6, 2027, provided he is a director on those dates.
Harris Bernard A Jr reported acquisition or exercise transactions in this Form 4 filing.
U S Physical Therapy director Bernard A. Harris Jr. received a grant of 2,306 shares of common stock as a restricted stock award. The grant was made at a reported transaction price of $0.00 per share and increased his direct holdings to 20,914 shares.
These 2,306 restricted shares vest in stages under the company’s Amended and Restated 2003 Stock Incentive Plan: 1,153 shares on August 20, 2026, 576 shares on November 20, 2026, and 577 shares on March 6, 2027, if he remains a director on those dates.
Gilmartin Kathleen A reported acquisition or exercise transactions in this Form 4 filing.
U.S. Physical Therapy director Kathleen A. Gilmartin received an award of 2,306 shares of Common Stock as a stock grant. The award was granted at a price of $0.00 per share as compensation, not an open-market purchase or sale.
After this grant, she holds 27,092 shares directly. The grant is in the form of restricted stock under the Company Amended and Restated 2003 Stock Incentive Plan, with portions scheduled to vest on specified future dates if she continues serving as a director.
Motsenbocker Anne reported acquisition or exercise transactions in this Form 4 filing.
U S Physical Therapy director Anne Motsenbocker received a grant of 2,306 shares of common stock at $61.61 per share as equity compensation. This award increased her direct holdings to 9,812 shares of the company’s stock.
The 2,306 granted shares are restricted stock. According to the terms, restrictions lapse as to 1,153 shares on August 20, 2026, 576 shares on November 20, 2026, and 577 shares on March 6, 2027, if she remains a director on those dates.
Swanson Regg E. reported acquisition or exercise transactions in this Form 4 filing.
U.S. Physical Therapy director Regg E. Swanson reported an equity award of company stock. He received a grant of 2,306 shares of common stock as restricted stock at a reference price of $61.61 per share, increasing his direct holdings to 15,492 shares.
The footnotes state these 2,306 restricted shares were granted under the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions are scheduled to lapse on August 20, 2026 for 1,153 shares, November 20, 2026 for 576 shares, and March 6, 2027 for 577 shares, if he remains a director on those dates. He also has 7,596 shares held indirectly through the Regg E. Swanson Revocable Trust, where he is beneficiary and trustee.
Minan Peter Francis reported acquisition or exercise transactions in this Form 4 filing.
U.S. Physical Therapy director Peter Francis Minan received a grant of 2,306 shares of Common Stock as restricted stock. The award is valued at $61.61 per share for reporting purposes and increases his direct holdings to 2,431 shares.
According to the grant terms, restrictions lapse as to 1,153 shares on August 20, 2026, 576 shares on November 20, 2026, and 577 shares on March 6, 2027, if he continues to serve as a director on those dates.
Harris Bernard A Jr reported acquisition or exercise transactions in this Form 4 filing.
U.S. Physical Therapy director Bernard A. Harris Jr. received 2,306 shares of common stock as a restricted stock award. The shares were granted at a reference price of $61.61 per share under the Company Amended and Restated 2003 Stock Incentive Plan. Following this grant, he directly holds 20,914 shares.
The award vests over time if he continues serving as a director. Restrictions lapse on 1,153 shares on August 20, 2026, 576 shares on November 20, 2026, and 577 shares on March 6, 2027, conditioned on his board service on those dates.
Gilmartin Kathleen A reported acquisition or exercise transactions in this Form 4 filing.
U.S. Physical Therapy director Kathleen A. Gilmartin received an award of 2,306 shares of Common Stock, valued at $61.61 per share. This restricted stock grant increases her direct holdings to 27,092 shares. Restrictions lapse in stages through March 6, 2027, contingent on continued board service.
U.S. Physical Therapy COO Graham D. Reeve sold 662 shares of common stock in an open-market transaction on March 11, 2026 at a weighted average price of $78.86 per share, with individual trade prices ranging from $78.82 to $79.82.
After this sale, he directly holds 30,078 shares, including 21,384 shares of restricted stock granted under the company’s stock incentive plan. These restricted shares are scheduled to vest in multiple tranches between May 20, 2026 and March 6, 2030, contingent on continued employment.
U.S. Physical Therapy COO Graham D. Reeve reported open-market sales of Common Stock through the Reeve Trust. The trust sold 1,807 shares on March 6, 2026 at $82.25 per share and 1 share on March 9, 2026 at $78.52 per share, for a total of 1,808 shares. After these indirect sales, the trust held no shares, while Reeve continued to own 30,740 shares directly as of March 6, 2026. This direct position includes 21,384 restricted shares that vest in scheduled installments between May 20, 2026 and March 6, 2030, contingent on continued employment.
U S Physical Therapy's Chief Financial Officer Carey P. Hendrickson reported a disposition of 10,000 shares of common stock back to the issuer. The Form 4 lists the transaction as a "Disposition to issuer" at a reported price of $0.00 per share, often indicating an administrative or compensation-related transfer rather than an open-market trade. Following this transaction, Hendrickson directly owns 27,808 shares of U S Physical Therapy common stock. A footnote explains that 11,070 of these shares are unvested restricted stock granted under the company’s stock incentive plan, scheduled to vest in tranches between May 20, 2026 and March 6, 2029, provided he remains employed on those dates.
U.S. Physical Therapy executive Richard Binstein, EVP, General Counsel and Secretary, sold 3,000 shares of common stock in an open-market transaction at $81.64 per share. After this sale, he directly owns 24,867 shares, including 21,070 restricted shares scheduled to vest in tranches between May 2026 and March 2030, subject to continued employment.
U.S. Physical Therapy, Inc. reported that Chairman and CEO Christopher J. Reading acquired 25,000 shares of common stock as a restricted stock grant under the company’s Amended and Restated 2003 Stock Incentive Plan. The award was recorded at a price of $0.00 per share as compensation, not an open-market purchase.
The restrictions on these 25,000 shares lapse in 15 equal quarterly installments of 1,562 shares beginning on May 20, 2026, with a final 1,570-share tranche vesting on March 6, 2030, subject to his continued employment. Following this grant, he directly holds 139,088 shares, including previously granted restricted stock with various vesting dates through 2030.
Williams Eric Joseph reported acquisition or exercise transactions in this Form 4 filing.
U S Physical Therapy reported that President and COO Eric Joseph Williams received a grant of 15,000 shares of common stock as restricted stock under the Amended and Restated 2003 Stock Incentive Plan. The award was recorded at a price of $0.0000 per share, indicating a non-cash equity grant.
The restrictions on these 15,000 shares lapse in fifteen equal quarterly installments of 936 shares on specified dates from May 20, 2026 through November 20, 2029, with a final 960 shares vesting on March 6, 2030, all subject to his continued employment. Following this grant, he directly holds 40,331 shares, including 31,322 restricted shares with a detailed vesting schedule extending from March 6, 2026 through March 6, 2030.
REEVE GRAHAM D. reported acquisition or exercise transactions in this Form 4 filing.
U.S. Physical Therapy COO Graham D. Reeve reported an equity award of 10,000 shares of common stock on February 23, 2026. The shares were granted as restricted stock under the company’s Amended and Restated 2003 Stock Incentive Plan at a price of $0.00 per share.
The restrictions lapse in 15 quarterly installments of 624 shares beginning May 20, 2026, plus 640 shares vesting on March 6, 2030, subject to continued employment. Following the grant, Reeve directly holds 30,740 shares, including 23,348 restricted shares with scheduled vesting through 2030, and indirectly holds 1,808 shares through the Reeve Trust.
Binstein Richard reported acquisition or exercise transactions in this Form 4 filing.
U.S. Physical Therapy (USPH) executive Richard Binstein received an equity award rather than buying shares on the market. He was granted 10,000 shares of common stock as restricted stock under the company’s Amended and Restated 2003 Stock Incentive Plan at a stated price of $0.0000 per share. These shares vest in 15 quarterly installments of 624 shares beginning on May 20, 2026 and on specified March 6, May 20, August 20, and November 20 dates through 2029, with a final 640-share installment vesting on March 6, 2030, in each case only if he remains employed by the company. Following this award, he directly owns 27,867 shares of common stock, including 22,624 restricted shares with multiple scheduled vesting dates between March 6, 2026 and March 6, 2030.
U.S. Physical Therapy, Inc. Chief Financial Officer Carey P. Hendrickson reported an acquisition of 10,000 shares of common stock as a restricted stock grant. The award carried a zero dollar price per share and increased his directly held total to 37,808 shares.
The 10,000-share grant vests in 15 equal quarterly installments of 624 shares from May 20, 2026 through November 20, 2029, plus 640 shares vesting on March 6, 2030, under the company’s Amended and Restated 2003 Stock Incentive Plan.
U.S. Physical Therapy, Inc. (USPH) filed a Form 4 reporting an insider stock sale by its COO. On 11/24/2025, the reporting officer sold 743 shares of common stock in an open market transaction at a weighted average price of $71.01 per share, with individual trade prices ranging from $71.01 to $71.31.
After this transaction, the officer beneficially owns 20,740 shares directly and 1,808 shares indirectly through the Reeve Trust. The filing notes that 13,348 of these shares were granted as restricted stock under the company’s Amended and Restated 2003 Stock Incentive Plan, with portions scheduled to vest in installments between March 2026 and March 2029, contingent on continued employment.
U.S. Physical Therapy, Inc. (USPH) director reported a purchase of company stock. On 11/20/2025, the reporting person bought 4,000 shares of common stock at a price of $69 per share, coded as a purchase transaction on a Form 4 filing. After this trade, the director beneficially owns 24,786 shares directly.
This total includes 471 restricted shares that were granted under the company’s Amended and Restated 2003 Stock Incentive Plan. These restricted shares will fully vest on March 6, 2026, provided she continues to serve on the Board of Directors through that date.